Scopus
YÖKSİS DOI Eşleşti
SJR Q3
mTOR inhibitors from a diagnostic perspective: radiolabeling of everolimus and its nanoformulation, in vitro incorporation assays against cervix and ovarian cancer cells
Journal of Radioanalytical and Nuclear Chemistry · Ocak 2022
YÖKSİS Kayıtları
mTOR inhibitors from a diagnostic perspective: radiolabeling of everolimus and its nanoformulation, in vitro incorporation assays against cervix and ovarian cancer cells
Journal of Radioanalytical and Nuclear Chemistry · 2022 SCI-Expanded
Doç. Dr. AHMET BİLGİ →
YÖKSİS Kayıtları — ISSN Eşleşmesi
Synthesis of a theranostic agent: radioiodinated PEGylated PLGA-indocyanine capsules and in vitro determination of their bioaffinity on ovarian, cervical and breast cancer cells
2016 ISSN: 0236-5731 SCI-Expanded Q3
Doç. Dr. AHMET BİLGİ →
Investigation of nanoformulation and incorporation potential of radiolabeled curcumin using HeLa and MDAH-2774 cells
2021 ISSN: 0236-5731 SCI-Expanded Q3
Doç. Dr. AHMET BİLGİ →
mTOR inhibitors from a diagnostic perspective: radiolabeling of everolimus and its nanoformulation, in vitro incorporation assays against cervix and ovarian cancer cells
2022 ISSN: 0236-5731 SCI-Expanded Q3
Doç. Dr. AHMET BİLGİ →
Assessment of natural radioactivity level of soil and water in the region of Çorlu (Turkey)
2021 ISSN: 0236-5731 SCI-Expanded Q2
Prof. Dr. MEHMET ERDOĞAN →
Synthesis and in vitro evaluation of 99mTc radiolabeled lapatinib (LPT) and its PLGA formulation
2024 ISSN: 0236-5731 SCI-Expanded Q2
Doç. Dr. AHMET BİLGİ →
Investigation of radiological effects in surface soil samples taken from the surroundings of Konya Beyşehir Lake
2024 ISSN: 0236-5731 SSCI
Dr. Öğr. Üyesi HAMİDE AVCI →
Makale Bilgileri
ISSN02365731
Yayın TarihiOcak 2022
Cilt / Sayfa331 · 171-178
Scopus ID2-s2.0-85118540207
Özet
mTOR inhibitors are recently important tools for cancer treatment. They act on cell growth regulation, proliferation, and survival. Pharmacological therapy with mTOR inhibitors such as everolimus is emerging as an alternate approach. Meanwhile, early diagnosis is a hot target in cancer research. Conversely, it can be a novel diagnosis approach to monitor mTOR inhibitors during their pathway. From this point of view, radiolabeling of everolimus and its nanoformulation (EVE-PLGA nanoparticles) in high yields (95%) with an important diagnostic radionuclide (technetium-99m) is described. Besides, in vitro incorporation assays of radiolabeled everolimus and its nanoformulation against the cervix and ovarian cancer cells were demonstrated 8- and 12-times high values than control group. In conclusion, radiolabeled everolimus and its nanoformulation have a promise to improve on monitoring mTOR inhibitors.
Yazarlar (9)
1
A. Bilgi
ORCID: 0000-0001-8682-1739
2
Ayfer Yurt Kilcar
ORCID: 0000-0003-0866-7515
3
Sevki Goksun Gokulu
ORCID: 0000-0002-6581-5716
4
Cansu Kayas
ORCID: 0000-0002-6030-3842
5
Nuri Yildirim
ORCID: 0000-0002-0605-4750
6
Kadriye Busra Karatay
ORCID: 0000-0002-2811-4689
7
Levent Akman
ORCID: 0000-0001-9399-8049
8
Fazilet Zumrut Biber Muftuler
ORCID: 0000-0001-8184-9660
9
Ahmet Aydin Ozsaran
Anahtar Kelimeler
Cervix and ovarian cancer cell lines
Everolimus (EVE)
mTOR inhibitor
Poly (lactic-co-glycolic acid) (PLGA)
SPECT tracer
Technetium-99 m ([ Tc]Tc) 99m
Kurumlar
Ege Üniversitesi
Izmir Turkey
Ege University Medical School
Izmir Turkey
Mersin Üniversitesi
Mersin Turkey
Selçuk Tip Fakültesi
Konya Turkey
Scimago Dergi (ISSN Eşleşmesi)
Journal of Radioanalytical and Nuclear Chemistry
Q3
SJR Skoru0,354
H-Index81
YayıncıSpringer Nature
ÜlkeSwitzerland
Analytical Chemistry (Q3)
Health, Toxicology and Mutagenesis (Q3)
Nuclear Energy and Engineering (Q3)
Pollution (Q3)
Public Health, Environmental and Occupational Health (Q3)
Radiology, Nuclear Medicine and Imaging (Q3)
Spectroscopy (Q3)
Metrikler
1
Atıf
9
Yazar
6
Anahtar Kelime